🇺🇸 FDA
Patent

US 11814428

Anti-PTCRA antibody-drug conjugates and uses thereof

granted A61KA61K47/68031A61K47/68033

Quick answer

US patent 11814428 (Anti-PTCRA antibody-drug conjugates and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K47/68031, A61K47/68033, A61K47/6849, A61K47/6897